Neogen Co. (NASDAQ:NEOG) Shares Bought by Blair William & Co. IL

Blair William & Co. IL boosted its position in shares of Neogen Co. (NASDAQ:NEOG) by 24.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,487,126 shares of the company’s stock after buying an additional 678,202 shares during the period. Blair William & Co. IL owned 1.61% of Neogen worth $54,504,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in NEOG. Covestor Ltd increased its position in Neogen by 173.2% during the first quarter. Covestor Ltd now owns 1,970 shares of the company’s stock worth $31,000 after buying an additional 1,249 shares during the period. Innealta Capital LLC acquired a new position in Neogen during the second quarter worth approximately $46,000. Headlands Technologies LLC increased its position in Neogen by 264.1% during the second quarter. Headlands Technologies LLC now owns 3,397 shares of the company’s stock worth $53,000 after buying an additional 2,464 shares during the period. Family Firm Inc. acquired a new position in Neogen during the second quarter worth approximately $90,000. Finally, Quantum Private Wealth LLC acquired a new position in Neogen during the second quarter worth approximately $156,000. Institutional investors and hedge funds own 96.73% of the company’s stock.

Insider Buying and Selling

In other Neogen news, Director James P. Tobin acquired 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were purchased at an average price of $16.86 per share, with a total value of $50,580.00. Following the completion of the acquisition, the director now directly owns 23,392 shares of the company’s stock, valued at approximately $394,389.12. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.71% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

NEOG has been the topic of a number of recent research reports. StockNews.com raised Neogen to a “sell” rating in a report on Friday, September 13th. Piper Sandler boosted their target price on Neogen from $17.00 to $17.50 and gave the company a “neutral” rating in a report on Tuesday, August 6th.

Neogen Trading Up 2.2 %

NASDAQ:NEOG opened at $17.24 on Thursday. The firm has a market cap of $3.73 billion, a P/E ratio of 1,724.00 and a beta of 1.21. The company has a current ratio of 3.82, a quick ratio of 2.59 and a debt-to-equity ratio of 0.28. The stock’s 50 day simple moving average is $16.54 and its 200-day simple moving average is $15.17. Neogen Co. has a 12-month low of $11.46 and a 12-month high of $20.89.

Neogen (NASDAQ:NEOG) last released its earnings results on Tuesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.02). Neogen had a negative net margin of 1.02% and a positive return on equity of 3.09%. The company had revenue of $236.80 million during the quarter, compared to analyst estimates of $225.83 million. During the same period in the previous year, the firm posted $0.14 EPS. The company’s revenue for the quarter was down 2.1% on a year-over-year basis. Equities analysts anticipate that Neogen Co. will post 0.54 EPS for the current year.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.